1001646-83-8

Basic information

• Product Name: N-tert-butoxycarbonyl-N-methyl-D-homophenylalanine
• Synonyms: N-tert-butoxycarbonyl-N-methyl-D-homophenylalanine
• CAS NO: 1001646-83-8
• Molecular Weight: 293.363
• Mol File: 1001646-83-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N-tert-butoxycarbonyl-N-methyl-D-homophenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: N-tert-butoxycarbonyl-N-methyl-D-homophenylalanine(1001646-83-8)
• EPA Substance Registry System: N-tert-butoxycarbonyl-N-methyl-D-homophenylalanine(1001646-83-8)

Safety Data

• Hazardous Substances Data: 1001646-83-8(Hazardous Substances Data)

Upstream product

• 100564-78-1 (2R)-(tert-butoxycarbonylamino)-4-phenylbutanoic acid 
• 74-88-4 methyl iodide 
• 37904-38-4 5-phenylpent-1-en-3-ol 
• 1404462-22-1 C₁₇H₂₅NO₂ 
• 1404462-19-6 C₁₄H₁₉NO 
• 1404461-83-1 N-methyl-5-phenylpent-1-en-3-amine 
• 1404461-82-0 N-(4-methoxyphenyl)-N-methyl-[1-(2-phenylethyl)prop-2-en-1-yl]amine 
• 1246927-41-2 5-phenylpent-1-en-3-yl 2,2,2-trichloroacetimidate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 1105971-79-6 (2S,4R)-4-(2-Aminoacetamido)-N-methyl-N-[(1R)-3-phenyl-1-(3-quinolylcarbamoyl)propyl]-2-pyrrolidinecarboxamide 

Relevant articles and documents

ENZYME INHIBITORS

The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 and *1 are as defined herein.

Rhodium-catalyzed regio- and enantioselective amination of racemic secondary allylic trichloroacetimidates with N-methyl anilines

We report the chiral diene ligated rhodium-catalyzed dynamic kinetic asymmetric transformation (DYKAT) of racemic secondary allylic trichloroacetimidates with a variety of N-methyl anilines, providing allylic N-methyl arylamines in high yields, regioselec

COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.